Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21581904 | 1.00 | KMT2A (0.40) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL29875636 | 1.00 | KMT2A (0.40) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL30112800 | 1.00 | KMT2A (0.40) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL29397011 | 1.00 | KMT2A (0.40) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL25322549 | 0.89 | KMT2A (0.38) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL29875681 | 0.89 | KMT2A (0.38) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL5501054 | 0.89 | KMT2A (0.38) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL27738280 | 0.89 | KMT2A (0.38) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL8494693 | 0.88 | FABP5 (0.41) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL4428638 | 0.87 | FABP5 (0.40) | KMT2AFABP5FABP7MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163354-B | Preparation method of N-fluorenylmethoxycarbonyl-N-trityl-L-asparagine | 常州吉恩药业有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115232195-A | Oligopeptide two-dimensional nanomaterial and application thereof | 忻州师范学院 | 2022-10-25 | — | — | CN | claimed |
| CN-114948860-A | Supermolecule hydrogel nano material, gelator, preparation method and application thereof | 东南大学 | 2022-08-30 | — | — | CN | claimed |
| CN-114163354-A | Preparation method of N-fluorenylmethoxycarbonyl-N-trityl-L-asparagine | 常州吉恩药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-120192365-A | Colipase inhibiting peptide and application thereof | 宜客美股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-114591944-B | High-sensitivity HPV virus detection kit | 杭州康大晨星医学科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118946593-A | Insulin hybrid peptide containing chymotrypsin inhibitory peptide and application thereof | 中国医学科学院药物研究所 | 2024-11-12 | — | — | CN | disclosed |
| CN-118725006-A | Process for preparing insoluble peptide | 南京金斯瑞生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118620022-A | Process for preparing phosphorylated polypeptides | 南京金斯瑞生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-115073587-B | Synthesis process for synthesizing bivalirudin by semi-continuous liquid phase synthesis | 厦门胜泽泰医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117720621-B | Alpha-amylase inhibiting peptide and application thereof | 北京晶泰科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117736255-A | Method for modifying polypeptide | 江苏金斯瑞生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2013091670-A1 | NOVEL JNK INHIBITOR MOLECULES FOR TREATMENT OF VARIOUS DISEASES | XIGEN S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
| EP-2582714-A2 | NOVEL JNK INHIBITOR MOLECULES | Xigen S.A. (CH) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011160653-A1 | NOVEL JNK INHIBITOR MOLECULES | XIGEN S.A. (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011160827-A2 | NOVEL JNK INHIBITOR MOLECULES | XIGEN S.A. (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| CN-102199195-A | Half-path charge matching amphiphilic self assembling short peptide, and its application as nanometer hemostatic material and hydrophobic drug carrier | UNIV SOUTH CHINA TECH | 2011-09-28 | — | — | CN | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| CN-101492494-A | Integrin ligand cyclic peptide analogues and cyclization method | UNIV ZHEJIANG (CN) | 2009-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | KMT2A 448/4885FABP5 885/4885FABP7 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.